Latent tuberculosis infection in the United States

New England Journal of Medicine

Volumn 364, Issue 15, 2011, Pages 1441-1448

  Horsburgh, C Robert ^a   Rubin, Eric J ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; GAMMA INTERFERON; ISONIAZID; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; BACTERIAL ANTIGEN; DIAGNOSTIC AGENT; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DIAGNOSTIC TEST; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG WITHDRAWAL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LEUKOPENIA; LIVER TOXICITY; MEDICAL DECISION MAKING; MIGRANT WORKER; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREEMPLOYMENT MEDICAL EXAMINATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TUBERCULIN TEST; UNITED STATES; ADULT; DRUG COMBINATION; FEMALE; HEALTH; IMMUNOLOGY; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; REVIEW; TUBERCULOSIS; VIRUS LATENCY;

ADULT; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-GAMMA; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; RIFAMPIN; TUBERCULOSIS; VIRUS LATENCY; WORLD HEALTH;

EID: 79954473147     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1005750     Document Type: Article

References (48)

1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-S247.
2. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-8. (Pubitemid 34755713)
3. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Recomm Rep 1999; 48(RR-9):1-13.
4. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the National Health and Nutrition Examination Survey, 1999-2000. Am J Respir Crit Care Med 2008;177:348-55. (Pubitemid 351198380)
5. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060-7.
6. Horsburgh CR Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-9.
7. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.
8. Marks SM, Taylor Z, Qualls NL, Shrestha- Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000;162:2033-8. (Pubitemid 32051659)
9. Kong PM, Tapy J, Calixto P, et al. Skintest screening and tuberculosis transmission among the homeless. Emerg Infect Dis 2002;8:1280-4. (Pubitemid 35334701)
10. Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless: a prospective study. Am J Respir Crit Care Med 2000;162:460-4. (Pubitemid 30647184)
11. Riley ED, Vlahov D, Huettner S, Beilenson P, Bonds M, Chaisson RE. Characteristics of injection drug users who utilize tuberculosis services at sites of the Baltimore city needle exchange program. J Urban Health 2002;79:113-27. (Pubitemid 34478027)
12. Grimes CZ, Hwang LY, Williams ML, Austin CM, Graviss EA. Tuberculosis infection in drug users: interferon-gamma release assay performance. Int J Tuberc Lung Dis 2007;11:1183-9. (Pubitemid 350146298)
13. Brassard P, Bruneau J, Schwartzman K, Sénécal M, Menzies D. Yield of tuberculin screening among injection drug users. Int J Tuberc Lung Dis 2004;8:988-93. (Pubitemid 39024902)
14. Salomon N, Perlman DC, Friedmann P, Ziluck V, Des Jarlais DC. Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program. Int J Tuberc Lung Dis 2000;4:47-54. (Pubitemid 30059284)
15. Lobato MN, Leary LS, Simone PM. Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med 2003;24:249-53. (Pubitemid 36349132)
16. Pablos-Méndez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis amongHispanics. Am J Public Health 1997;87: 574-9. (Pubitemid 27208742)
17. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
18. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26. (Pubitemid 43235123)
19. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92. (Pubitemid 40994319)
20. Palmer CE, Jablon S, Edwards PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc 1957;76:517-39.
21. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 2007;167:335-42. (Pubitemid 46333932)
22. Linas B, Freedberg K, Horsburgh C. Revisiting the effectiveness of LTBI screening in the United States. Am J Respir Crit Care Med 2009;179:A5283. abstract.
23. Ozuah PO, Burton W, Lerro KA, Rosenstock J, Mulvihill M. Assessing the validity of tuberculin skin test readings by trained professionals and patients. Chest 1999;116:104-6. (Pubitemid 29340268)
24. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-75. (Pubitemid 23358739)
25. Todryk SM, Pathan AA, Keating S, et al. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 2009; 128:83-91.
26. Sarrazin H, Wilkinson KA, Andersson J, et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J Infect Dis 2009;199:702-10.
27. Pollock NR, Campos-Neto A, Kashino S, et al. Discordant QuantiFERON-TB Gold test results among US healthcare workers with increased risk of latent tuberculosis infection: a problem or solution? Infect Control Hosp Epidemiol 2008;29:878-86.
28. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a wholeblood interferon-gamma release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011;183:88-95.
29. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-204. (Pubitemid 44713473)
30. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1- infected individuals. Clin Infect Dis 2009; 48:954-62.
31. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010;35:1346-53.
32. Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzymelinked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007;150:238-44. (Pubitemid 47609557)
33. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011;56:230-8.
34. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008;149:689-97.
35. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-6.
36. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. (Pubitemid 40381339)
37. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
38. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-8. (Pubitemid 27391629)
39. Matteelli A, Olliaro P, Signorini L, et al. Tolerability of twice-weekly rifabutinisoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis 1999;3:1043-6.
40. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-7. (Pubitemid 35176096)
41. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-9. (Pubitemid 39214621)
42. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25.
43. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. Can Commun Dis Rep 2008;34:1-13.
44. Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection - 2010 update. Can Commun Dis Rep 2010;36: 1-21.
45. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its control. March 2011.
46. Belknap R, Kelaher M, Wall K, Daley C, Schluger N, Reves R. Reproducibility, repeatability and 6 month follow-up with interferon-gamma release assays (IGRAs). Presented at the 105th International Conference of the American Thoracic Society, San Diego, CA, May 15-20, 2009.
47. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug- resistant tuberculosis. N Engl J Med 2009;360:2397-405.
48. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007;196:Suppl 1:S28-S34. (Pubitemid 47206082)